TCGA-E2-A572-01A-13R-A31O-07
— · B
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- B
- subtype
- B
- overall_survival_months
- 40
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- OXIDATIVE_PHOSPHORYLATION+0.460
- INTERFERON_ALPHA_RESPONSE+0.310
- PANCREAS_BETA_CELLS+0.310
- FATTY_ACID_METABOLISM+0.280
- KRAS_SIGNALING_DN+0.280
- MYOGENESIS+0.270
- BILE_ACID_METABOLISM+0.210
- ESTROGEN_RESPONSE_LATE+0.200
- PEROXISOME+0.190
- XENOBIOTIC_METABOLISM+0.180
Top 10 suppressed
- G2M_CHECKPOINT-0.530
- MITOTIC_SPINDLE-0.530
- E2F_TARGETS-0.490
- UV_RESPONSE_DN-0.440
- TGF_BETA_SIGNALING-0.420
- PROTEIN_SECRETION-0.400
- WNT_BETA_CATENIN_SIGNALING-0.400
- IL6_JAK_STAT3_SIGNALING-0.390
- TNFA_SIGNALING_VIA_NFKB-0.380
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.370
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-LL-A6FQ-01A-11R-A31O-07 | — | B | 0.914 |
| 2 | TCGA-AQ-A54O-01A-11R-A266-07 | — | B | 0.890 |
| 3 | MNG908 | — | — | 0.889 |
| 4 | 20140057.LumB | — | B | 0.886 |
| 5 | TCGA-LL-A50Y-01A-11R-A266-07 | — | B | 0.863 |
| 6 | ERR2598282 | fetal | fetal | 0.859 |
| 7 | TCGA-AC-A3YJ-01A-11R-A22U-07 | — | B | 0.857 |
| 8 | TCGA-GD-A6C6-01A-21R-A31N-07 | — | — | 0.847 |
| 9 | TCGA-LL-A5YM-01A-11R-A28M-07 | — | B | 0.843 |
| 10 | MDT-AP-2103 | Med | Medulloblastoma | 0.833 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 19 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| OXIDATIVE_PHOSPHORYLATION | 0.460 | Remibrutinib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.310 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.310 | Cobimetinib | — uncovered |
| FATTY_ACID_METABOLISM | 0.280 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.280 | Remibrutinib | — uncovered |
| MYOGENESIS | 0.270 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.210 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.200 | Idelalisib | — uncovered |
| PEROXISOME | 0.190 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.180 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.160 | Inavolisib | — uncovered |
| COAGULATION | 0.130 | Binimetinib | — uncovered |
| DNA_REPAIR | 0.130 | Idelalisib | — uncovered |
| UV_RESPONSE_UP | 0.120 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.110 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.090 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.060 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.010 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.010 | Idelalisib | — uncovered |